Drug Trial Radar · NCT06228326
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Apr 17, 2024
Primary completion
Feb 2027
Study completion Jul 2028
Sponsor
- Lead sponsor
- Krystal Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies. This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect of KB707. Monotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid tumor malignancies affecting the lungs who had progressed on standard of care therapy, cannot tolerate standard of care therapy, or refused standard of care therapy. The dose escalation phase (Cohorts 1 and 2) evaluated KB707 monotherapy using a standard 3+3 design, followed by a dose expansion phase (Cohort 4) to further evaluate the selected dose. Subjects received inhaled KB707 weekly for three weeks, then every three weeks. The dose escalation portion of the study is now complete, and the selected dose is being evaluated in the expansion phase. Combination regimens with a selected (fixed) dose of KB707 are being evaluated in subjects with advanced or metastatic non-small cell lung cancer (NSCLC). Subjects in Cohorts 5 and 6 are receiving inhaled KB707 once every 2 weeks (q2w), delivered in combination with Keytruda once every 6 weeks. Subjects in Cohort 7 are receiving inhaled KB707 in combination with docetaxel once every 3 weeks. All subjects will be treated until tumor progression, death, unacceptable toxicity, symptomatic deterioration, achievement of maximal response, subject choice, Investigator decision to discontinue treatment, or the Sponsor determines to terminate the study.
Conditions
- Lung Cancer, Non-small Cell
- Lung Cancer Metastatic
- Solid Tumor, Adult
- Advanced Cancer
- Lung Cancer (NSCLC)
Interventions
KB707Biological
Genetically modified herpes simplex type 1 virus
Pembrolizumab (KEYTRUDA®)Drug
PD-1 immune checkpoint inhibitor
ChemotherapyDrug
SOC chemotherapy
DocetaxelDrug
SOC chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of inhaled KB707 based upon assessment of adverse events (AE)Time frame: up to 36 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
XCancer Research Network/Dothan Hematology & Oncology
Dothan, Alabama · Recruiting
HonorHealth Research Institute
Scottsdale, Arizona · Recruiting
Precision NextGen Oncology
Beverly Hills, California · Recruiting
Emad Ibrahim MD Inc
Redlands, California · Recruiting
BRCR Global
Weston, Florida · Recruiting
IU Simon Comprehensive Cancer Center
Indianapolis, Indiana · Terminated
Ochsner/MD Anderson Cancer Center
New Orleans, Louisiana · Recruiting
Henry Ford Health
Detroit, Michigan · Recruiting
Gabrail Cancer Center Research
Canton, Ohio · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Terminated
Sarah Cannon Research Institute
Nasville, Tennessee · Recruiting
Renovatio Clinical
El Paso, Texas · Terminated
Renovatio Clinical
The Woodlands, Texas · Terminated
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.